|
Showing 1 - 10 of
10 matches in All Departments
As the global population ages the impact of neurodegenerative
diseases like Alzheimer's disease and Parkinson's disease are
significant forces in shaping human health and quality of life in
the 21st century. Insights into understanding these diseases, and
knowing how to treat them are major frontiers of scientific
research. Neurodegenerative Diseases: Unifying Principles is the
result of a conceptual revolution over the last decade in our
understanding of neurodegenerative diseases as sharing unifying
features. There is an increasing appreciation of the common
biological and pathological features across seemingly varied
neurodegenerative diseases that entail protein misfolding
dysfunction and its consequences over time. Providing an overview
of this conceptual change is the main theme for the book.
Conventional approach emphasize the differences among
neurodegenerative disorders, here Drs. Cummings and Pillai compile
the increasingly compelling evidence that these disorders share
many features and that insights in one may be rapidly translated
into advances in another. The goal is to accelerate understanding
by showing linkages among biological, pathological, can clinical
aspects of this class of diseases. This collection of 19,
inter-related chapters, articulates and broadens our view of the
unifying features that initiate and drive disease progression
across a variety of neurodegenerative diseases over time. This book
will serve as an outstanding sourcebook of insights from experts
that have played key roles in this story.
Growth in the incidence of dementia presents major challenges to
global healthcare systems. As the burden of dementia in non-Western
cultures grows, developing nations are expected to overtake
developed nations in terms of dementia prevalence. Insights from
developing nations and transcultural considerations are,
nevertheless, neglected in the published literature. Dementia: A
Global Approach fills this gap by integrating contemporary
cross-cultural knowledge about dementia. Each section reviews the
literature from the published, predominantly Western, perspective,
contrasting it with empirical knowledge from non-Western cultures.
Covering major clinical, epidemiological and scientific areas of
interest, detailed consideration is also given to care-giving
models across the world and management of patients who have
migrated between regions. Enriched with personal insights from
clinical experts across the globe, this is a key text for
neurologists, geriatricians, psychiatrists, psychologists,
epidemiologists and all those responsible for managing provisions
of dementia services.
Published annually, volumes in this series provide readers with
updates of recent clinical trial results, impacts of trials on
guidelines and evidence-based practice, advances in trial
methodologies, and the evolution of biomarkers in trials. The
series focuses on trials in neurotherapeutics, including
disease-modifying and symptomatic agents for neurological diseases,
psychopharmacological management of neurologic and psychiatric
illnesses, and non-drug treatments. Each paper is authored by a
leader in the area of neurotherapeutics and clinical trials, and
the series is guided by an editor-in-chief and editorial board with
broad experience in drug development and neuropsychopharmacology.
Progress in Neurotherapeutics and Neuropsychopharmacology is an
essential update of recent trials in all aspects of the management
of neurologic and neuropsychiatric disorders, and will be an
invaluable resource for practising neurologists as well as clinical
and translational neuroscientists.
Published annually, volumes in this series provide readers with
updates of recent clinical trial results, impacts of trials on
guidelines and evidence-based practice, advances in trial
methodologies, and the evolution of biomarkers in trials. The
series focuses on trials in neurotherapeutics, including
disease-modifying and symptomatic agents for neurological diseases,
psychopharmacological management of neurologic and psychiatric
illnesses, and non-drug treatments. Each paper is authored by a
leader in the area of neurotherapeutics and clinical trials, and
the series is guided by an editor-in-chief and editorial board with
broad experience in drug development and neuropsychopharmacology.
Progress in Neurotherapeutics and Neuropsychopharmacology is an
essential update of recent trials in all aspects of the management
of neurologic and neuropsychiatric disorders, and will be an
invaluable resource for practising neurologists as well as clinical
and translational neuroscientists. Also available electronically
http: //www.journals.cambridge.org/jid_PNN.
For nearly 30 years, the Concise Guide to Neuropsychiatry and
Behavioral Neurology has been an indispensable companion for
clinicians caring for patients struggling with everything from
delusions and hallucinations to aphasia and stroke. This third
edition combines all of the scientific rigor of its predecessors
with a renewed emphasis on kind, empathetic care. It has been
updated to account for the development of new techniques in brain
imaging; improvement in electrophysiological methods to better
detect epilepsy and sleep disorders; and a growing list of blood
and spinal fluid biomarkers that have revolutionized diagnostic
capability. Readers will benefit from guidance on novel treatments
and improved therapies for a range of disorders that includes *
Memory disorders* Movement disorders* Brain tumors* Substance
related disorders* HIV neurocognitive disorders A wealth of tables
throughout the book will help busy clinicians quickly reference
relevant information, regardless of the patient's presentation. And
an extensive list of recommended readings opens the door to further
study. As useful for trainees as it is for the experienced
practitioner, the Concise Guide to Neuropsychiatry and Behavioral
Neurology, Third Edition offers the latest science and expert
guidance to both achieve accurate diagnosis and undertake effective
management of patients with complex neuropsychiatric and
neurobehavioral disorders.
This is the long-awaited new edition of Jeffrey Cummings' classic work, Clinical Neuropsychiatry, originally published in 1985. That book represented an integration of behavioural neurology and biological psychiatry into a single volume devoted to explicating brain-behaviour relationships. It was clinically oriented and intended for practitioners caring for patients with neuropsychiatric disorders. The new title reflects the authors' effort to link the recent explosion of new information from neurochemistry, neuroanatomy, genetics, neuropharmacology, neuropathology, and neuroimaging to the clinical descriptions. Yet the clinical emphasis of its predecessor has been maintained. Each chapter has a consistent approach and the book as whole provides a practical, easy-to-use synthesis of clinical advice and basic science. The volume is enchanced by 4-colour images throughout. It is intended for students, residents, fellows, and practitioners of neurology, psychiatry, neuropsychology, and cognitive neuroscience. It will also be interest to individuals in neuroimaging.
Published annually, volumes in this series provide readers with
updates of clinical trial results, impacts of trials on guidelines
and evidence-based practice, advances in trial methodologies, and
the evolution of biomarkers in trials. The series focuses on trials
in neurotherapeutics, including disease-modifying and symptomatic
agents for neurological diseases, psychopharmacological management
of neurologic and psychiatric illnesses, and non-drug treatments.
Each paper is authored by a leader in the area of neurotherapeutics
and clinical trials, and the series is guided by an editor-in-chief
and editorial board with broad experience in drug development and
neuropsychopharmacology. Progress in Neurotherapeutics and
Neuropsychopharmacology is an essential update of trials in all
aspects of the management of neurologic and neuropsychiatric
disorders, and will be an invaluable resource for practising
neurologists as well as clinical and translational neuroscientists.
Published annually, volumes in this series provide readers with
updates of clinical trial results, impacts of trials on guidelines
and evidence-based practice, advances in trial methodologies, and
the evolution of biomarkers in trials. The series focuses on trials
in neurotherapeutics, including disease-modifying and symptomatic
agents for neurological diseases, psychopharmacological management
of neurologic and psychiatric illnesses, and non-drug treatments.
Each paper is authored by a leader in the area of neurotherapeutics
and clinical trials, and the series is guided by an editor-in-chief
and editorial board with broad experience in drug development and
neuropsychopharmacology. Progress in Neurotherapeutics and
Neuropsychopharmacology is an essential update of trials in all
aspects of the management of neurologic and neuropsychiatric
disorders, and will be an invaluable resource for practising
neurologists as well as clinical and translational neuroscientists.
This volume was first published in 2006.
Published annually, volumes in this series provide readers with
updates of recent clinical trial results, impacts of trials on
guidelines and evidence-based practice, advances in trial
methodologies, and the evolution of biomarkers in trials. The
series focuses on trials in neurotherapeutics, including
disease-modifying and symptomatic agents for neurological diseases,
psychopharmacological management of neurologic and psychiatric
illnesses, and non-drug treatments. Each paper is authored by a
leader in the area of neurotherapeutics and clinical trials, and
the series is guided by an editor-in-chief and editorial board with
broad experience in drug development and neuropsychopharmacology.
Progress in Neurotherapeutics and Neuropsychopharmacology" is an
essential update of recent trials in all aspects of the management
of neurologic and neuropsychiatric disorders, and will be an
invaluable resource for practicing neurologists as well as clinical
and translational neuroscientists.
Behavior and Mood Disorders in Focal Brain Lesions takes a unique approach to presenting the emotional and behavioral consequences of focal lesions affecting the brain to summarize the current state of research and provide a basis for improved patient care. This is the first clinical reference work to specifically address the relationship of focal brain dysfunction to behavioral and emotional disorders, providing the most comprehensive account available of these manifestations of brain lesions including stroke, trauma, epilepsy, multiple sclerosis, and even neurosurgery. A worldwide team of neuroscientists and clinicians examines the links between regional brain dysfunction and disorders of mood, thought and affect processing, and behavior. Chapters are devoted to methodological issues, lesions of specific sites, such as the frontal lobes, basal ganglia, and thalamus, and symptoms such as mood disorder, violent behavior, and anosognosia.
|
|